About wave life sciences - WVE
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
WVE At a Glance
Wave Life Sciences Ltd.
Marina One East Tower
Singapore, Central Singapore 018936
| Phone | 65-6236-3388 | Revenue | 113.31M | |
| Industry | Biotechnology | Net Income | -57,513,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 3,005.097% | |
| Fiscal Year-end | 12 / 2024 | Employees | 268 | |
| View SEC Filings |
WVE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.729 |
| Price to Book Ratio | 15.185 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.386 |
| Enterprise Value to Sales | 3.313 |
| Total Debt to Enterprise Value | 0.086 |
WVE Efficiency
| Revenue/Employee | 422,779.851 |
| Income Per Employee | -214,600.746 |
| Receivables Turnover | 5.373 |
| Total Asset Turnover | 0.538 |
WVE Liquidity
| Current Ratio | 1.262 |
| Quick Ratio | 1.262 |
| Cash Ratio | 1.075 |
WVE Profitability
| Gross Margin | 91.875 |
| Operating Margin | -60.011 |
| Pretax Margin | -51.357 |
| Net Margin | -50.759 |
| Return on Assets | -27.30 |
| Return on Equity | -1,118.169 |
| Return on Total Capital | -72.233 |
| Return on Invested Capital | -169.632 |
WVE Capital Structure
| Total Debt to Total Equity | 67.611 |
| Total Debt to Total Capital | 40.338 |
| Total Debt to Total Assets | 11.681 |
| Long-Term Debt to Equity | 64.103 |
| Long-Term Debt to Total Capital | 31.906 |